Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma

NCT07139509 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

18

Enrollment

OTHER_GOV

Sponsor class

Conditions

Relapsed/Refractory Multiple Myeloma(MM)

Interventions

DRUG: allogeneic cord blood-derived, dual-targeting CD19/BCMA CAR-T cells

Sponsor

Xi'an No.3 Hospital

Collaborators

[object Object]